TY - JOUR
T1 - Management of renal osteodystrophy with 1,25(OH)2D3. II. Effects on histopathology of bone
T2 - Evidence for healing of osteomalacia
AU - Malluche, H. H.
AU - Goldstein, D. A.
AU - Massry, S. G.
PY - 1979
Y1 - 1979
N2 - The effects of 6 months of therapy with 1,25(OH)2D3 on bone histology were evaluated in 12 dialysis patients. They all displayed evidence of bone disease consisting of osteitis fibrosa and osteomalacia of varying degrees and predominance. Therapy with 1,25-(OH)2D3 was associated with: decrease in osteoclastic activity; reduction or disappearance of endosteal fibrosis; - this improvement was independent of changes in serum iPTH levels; decrease in woven osteoid; decrease or normalization of osteoid volume, and normalization of bone mineralization. The data indicate that long-term therapy with 1,25(OH)2D3 can improve hyperparathyroid bone disease, restore bone architecture and heal osteomalacia.
AB - The effects of 6 months of therapy with 1,25(OH)2D3 on bone histology were evaluated in 12 dialysis patients. They all displayed evidence of bone disease consisting of osteitis fibrosa and osteomalacia of varying degrees and predominance. Therapy with 1,25-(OH)2D3 was associated with: decrease in osteoclastic activity; reduction or disappearance of endosteal fibrosis; - this improvement was independent of changes in serum iPTH levels; decrease in woven osteoid; decrease or normalization of osteoid volume, and normalization of bone mineralization. The data indicate that long-term therapy with 1,25(OH)2D3 can improve hyperparathyroid bone disease, restore bone architecture and heal osteomalacia.
UR - http://www.scopus.com/inward/record.url?scp=0018763813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018763813&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0018763813
SN - 0378-0392
VL - 2
SP - 48
EP - 55
JO - Mineral and Electrolyte Metabolism
JF - Mineral and Electrolyte Metabolism
IS - 1
ER -
